Idarubicin
Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation
The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide Alice Mims | Phase 3 | BBB |
Daunomycin National Cancer Institute (NCI) | Phase 3 | BBB |
Cytarabine The First Affiliated Hospital of Soochow University | Phase 3 | BBB |
Mitoxantrone BGI, China | Phase 2 | BBB |
Cyclophosphamide BGI, China | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Idarubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →